antibodi
valuabl
molecul
diagnost
treatment
diseas
caus
pathogen
toxin
tradit
antibodi
gener
hybridoma
technolog
altern
hybridoma
technolog
use
antibodi
phage
display
gener
recombin
antibodi
vitro
technolog
circumv
limit
immun
system
allowsin
theoryth
gener
antibodi
conceiv
molecul
phage
display
technolog
enabl
obtain
human
antibodi
antibodi
gene
librari
either
patient
avail
immun
ethic
feasibl
hand
patient
immunizedinfect
anim
avail
common
construct
immun
phage
display
librari
select
vivo
affinitymatur
antibodi
phage
packag
dna
sequenc
encod
antibodi
directli
avail
antibodi
smoothli
engin
accord
requir
final
applic
review
overview
phage
display
deriv
recombin
antibodi
bacteri
viral
eukaryot
pathogen
well
toxin
diagnost
therapi
given
antibodi
essenti
molecul
tool
basic
research
diagnost
therapi
pastand
still
todaypolyclon
antibodi
produc
serum
anim
like
hors
mileston
antibodi
gener
develop
hybridoma
technolog
allow
product
monoclon
antibodi
hybridoma
technolog
drawback
like
limit
number
candid
possibl
instabl
aneuploid
cell
line
inabl
provid
antibodi
highli
conserv
antigen
limit
applic
gener
human
antibodi
hybridoma
technolog
essenti
give
murin
antibodi
use
diagnost
research
purpos
howev
therapeut
applic
limit
repeat
administr
murin
antibodi
caus
human
antimous
antibodi
reaction
reduc
antibodi
halflif
lead
sever
side
effect
anaphylact
shock
strategi
circumv
problem
antibodi
human
use
transgen
anim
origin
antibodi
gene
repertoir
replac
human
gene
repertoir
anoth
strategi
human
hybridoma
technolog
result
human
antibodi
although
technolog
problem
murin
hybridoma
technolog
regard
limit
immun
system
technolog
overcom
limit
immun
system
antibodi
phage
display
sinc
technolog
involv
vitro
select
process
complet
independ
immun
system
display
method
commonli
use
today
base
work
georg
p
smith
filament
phage
infect
e
coli
select
process
call
pan
refer
gold
digger
tool
phage
display
technolog
develop
antibodi
three
place
parallel
heidelberg
germani
cambridg
uk
la
jolla
usa
two
differ
genet
system
develop
express
antibodi
piii
phage
protein
iii
fusion
protein
phage
display
first
antibodi
gene
directli
insert
phage
genom
fuse
upstream
wildtyp
piii
gene
second
success
system
uncoupl
antibodi
express
phage
propag
provid
gene
encod
antibodi
piii
fusion
protein
separ
plasmid
call
phagemid
contain
phage
morphogenet
signal
packag
vector
phage
particl
matter
use
phage
display
system
antibodi
fragment
display
surfac
phage
correspond
antibodi
gene
packag
phage
particl
phage
display
technolog
use
phage
lambda
less
suitabl
display
antibodi
fragment
addit
phage
lytic
phage
aggrav
practic
work
common
antibodi
format
use
antibodi
phage
display
singl
chain
fragment
variabl
scfv
fragment
antigen
bind
fab
antibodi
format
use
phage
display
singl
chain
fab
scfab
human
vh
domain
dab
variabl
domain
camel
heavi
chain
vhh
immunoglobulin
shark
ignar
figur
show
antibodi
phage
differ
antibodi
fragment
veterinari
research
chicken
librari
often
use
contrast
occur
human
divers
chicken
antibodi
gene
result
gene
convers
nand
ctermin
part
chicken
vh
vl
alway
ident
facilit
antibodi
gene
amplif
librari
clone
also
rabbit
phage
display
use
gener
antibodi
pathogen
select
process
pan
antigen
immobil
solid
surfac
like
column
matrix
magnet
bead
plastic
surfac
high
proteinbind
capac
polystyren
tube
respect
microtitr
well
common
method
option
pan
solut
use
biotinyl
antigen
follow
pulldown
streptavidin
bead
vast
excess
nonbind
antibodi
phage
remov
stringent
wash
subsequ
bound
antibodi
phage
elut
eg
ph
shift
trypsin
reamplifi
infect
e
coli
infect
phagemid
bear
e
coli
helperphag
new
antibodi
phage
produc
select
cycl
repeat
number
antigenspecif
antibodi
phage
clone
increas
everi
pan
round
usual
pan
round
perform
final
monoclon
antibodi
phage
monoclon
solubl
antibodi
identifi
eg
elisa
immunoblot
flow
cytometri
antibodi
fragment
gene
subclon
antibodi
format
eg
scfvfc
igg
schema
select
process
given
fig
regard
sourc
gene
antibodi
select
two
type
librari
immun
librari
univers
librari
immun
librari
construct
immunizedinfect
donor
typic
use
medic
research
obtain
antibodi
particular
target
antigen
eg
infecti
pathogen
like
ebola
viru
advantag
kind
librari
vgene
contain
hypermut
affin
matur
although
develop
restrict
ethic
constraint
altern
univers
singl
pot
librari
includ
semisynthet
synthet
librari
design
isol
antibodi
fragment
bind
everi
possibl
antigen
least
theori
librari
construct
rearrang
v
gene
b
cell
igm
nonimmun
donor
exampl
librari
type
human
fab
librari
construct
de
haard
colleagu
hal
scfv
librari
semisynthet
librari
construct
unrearrang
v
gene
preb
cell
germlin
cell
one
antibodi
framework
one
sever
cdr
alway
cdr
random
often
use
semisynthet
librari
tomlinson
j
librari
use
one
defin
framework
kappa
random
combin
synthet
repertoir
use
antibodi
gene
librari
librari
light
chain
autoimmun
patient
combin
fd
fragment
contain
synthet
human
framework
region
origin
autoimmun
patient
fulli
synthet
librari
made
human
framework
random
cdr
cassett
theoret
size
univers
librari
usual
higher
independ
clone
date
antibodi
antibodi
conjug
approv
ema
andor
fda
statu
januari
http
wwwimgtorgmabdbqueryact
develop
statu
phase
search
field
antibodi
develop
approv
therapeut
antibodi
cancer
autoimmun
diseas
annual
sale
therapeut
antibodi
exceed
billion
us
mechan
therapeut
antibodi
manifold
includ
neutral
substanc
eg
toxin
cytokin
like
tumor
necrosi
factor
alpha
block
receptor
like
epiderm
growth
factor
receptor
bind
cell
modul
host
immun
system
combin
effect
current
two
recombin
antibodi
approv
treatment
pathogen
toxin
raxibacumab
human
antibodi
anthrax
treatment
deriv
phage
display
librari
cambridg
antibodi
technolog
medimmun
part
astrazeneca
cooper
human
genom
scienc
glaxosmithklin
antibodi
palivizumab
treatment
respiratori
syncyti
viru
bronchiol
classic
human
antibodi
antibodi
also
deriv
phage
display
clostridium
difficil
antibodi
bezlotoxumab
clinic
phase
overview
recombin
antibodi
deriv
phage
display
bacteri
viral
pathogen
eukaryot
pathogen
parasit
fungi
toxin
well
detail
exampl
diagnost
therapi
given
next
section
therapeut
antibodi
bacteri
target
gener
toxin
antibodi
describ
section
recombin
antibodi
toxin
major
antibodi
bacteria
develop
order
facilit
diagnost
patient
environment
sampl
gener
cultur
microbi
detect
bacteria
regard
standard
diagnost
mani
pathogen
eg
mycobacterium
tuberculosi
salmonella
typhimurium
sinc
method
often
timeconsum
requir
experienc
lab
person
high
throughput
analysi
often
limit
realtim
pcr
measur
develop
diagnost
mani
bacteria
offer
high
sensit
specif
detect
sampl
treatment
still
need
mani
case
includ
expens
complex
laboratori
devic
approach
ms
diagnost
technolog
need
expens
devic
antibodybas
diagnost
like
elisa
would
simpl
easi
use
also
develop
countri
order
gener
antibodi
desiredbind
properti
phagedisplay
use
select
antibodi
protein
polysaccharid
chlamydophila
psittaci
chlamydia
trachomati
haemophilu
influenza
listeria
monocytogen
mycobaterium
bovi
mycobacterium
tuberculosi
porphyromona
gingivali
ralstonia
solanacearum
salmonella
typhimurium
yersinia
pesti
even
select
cell
lysat
whole
cell
perform
mycobacterium
avium
bacillu
anthraci
moraxella
catarrhali
lawsonia
intracellulari
lactobacillu
acidophilu
helicobact
pylori
brucella
melitensi
bordetella
pertussi
follow
paragraph
give
detail
exampl
antibodi
gener
use
phage
display
antibodi
engin
differ
bacteri
pathogen
tuberculosi
tb
bacteri
infect
caus
mycobacterium
tuberculosi
mtb
pathogen
particular
cell
wall
membran
characterist
abl
infect
multipli
within
alveolar
macrophag
lead
cough
weak
fever
million
peopl
infect
million
die
worldwid
order
improv
treatment
control
diseas
spread
tb
must
diagnos
earli
possibl
one
promin
target
purpos
bacteri
antigen
abund
protein
secret
mtb
complex
three
highli
homolog
protein
molecular
size
kda
novel
approach
ferrara
et
al
monoclon
antibodi
select
complex
combin
phageand
yeastdisplay
first
scfvlibrari
preselect
phage
display
reduc
divers
uniqu
scfv
clone
coloni
form
unit
second
enrich
sublibrari
clone
yeastdisplay
system
clone
select
output
screen
individu
antigen
bind
fac
highest
antigenbind
signal
sort
analyz
total
clone
sequenc
reveal
genet
uniqu
scfv
clone
screen
assay
identifi
seven
antibodi
pair
detect
concentr
nm
absenc
serum
nm
presenc
interestingli
none
antibodi
absolut
specif
one
subunit
complex
three
subunit
b
c
bound
although
equal
contrast
fuch
et
al
select
five
human
antibodi
recombin
protein
librari
three
bound
specif
protein
elisa
lod
ngml
even
sandwich
detect
recombin
elisa
lod
ngml
integr
later
flow
immuno
assay
lod
ngml
shown
antigen
detect
mtb
cell
extract
cultur
filtrat
restrict
direct
elisa
immunoblot
assay
author
paper
argu
select
antibodi
must
affin
matur
order
reach
requir
detect
limit
success
implement
concept
demonstr
sixholo
et
al
chicken
antibodi
select
semisynthet
nkuku
librari
kda
recombin
antigen
tuberculosi
also
known
heat
shock
protein
x
hspx
four
round
pan
three
scfv
identifi
elisa
clone
lowest
elisa
signal
select
vitro
engin
use
two
differ
approach
first
mutant
librari
gener
parent
scfv
errorpron
pcr
divers
uniqu
scfv
librari
select
hspx
antigen
stringent
condit
lead
identif
three
mutant
scfv
contain
one
three
individu
amino
acid
exchang
occur
cdr
framework
region
mutant
show
increas
elisabind
signal
reach
signal
time
higher
compar
parent
scfv
furthermor
mutant
show
improv
associ
dissoci
kinet
elisa
spr
analysi
approach
length
scfv
linker
reduc
amino
acid
singl
glycin
residu
forc
tetramer
antibodi
due
cooper
bind
appar
function
affin
improv
elisa
tetramer
scfv
gener
time
higher
elisa
signal
spr
prove
increas
associ
decreas
dissoci
rate
porphyromona
gingivali
one
major
pathogen
involv
periodont
periodont
inflammatori
diseas
caus
loosen
loss
teeth
secret
cystein
proteas
like
rgpb
contribut
diseas
patholog
repres
potenti
biomark
diseas
detect
progress
skottrup
et
al
gener
antibodi
librari
camel
divers
clone
special
featur
antibodi
consist
singl
monomer
vhh
domain
also
call
nanobodi
advantag
format
small
size
kda
eas
product
e
coli
convex
paratop
form
enabl
target
cryptic
epitop
librari
select
immobil
rgpb
one
clone
isol
bind
specif
cell
surfac
display
solubl
rgpb
affin
pm
detect
limit
cellsml
saliva
reach
test
subtract
inhibit
elisa
catalyt
activ
rgpb
inhibit
antibodi
bind
salmonella
typhimurium
one
import
pathogen
foodborn
gastrointestin
infect
meyer
et
al
first
identifi
novel
immunogen
protein
typhimurium
genom
librari
use
oligopeptid
phage
display
second
step
human
antibodi
select
target
hal
gene
librari
diva
differenti
infect
vaccin
anim
vaccin
develop
typhimurium
strain
lack
marker
protein
eg
ompd
outer
membran
protein
develop
diva
vaccin
allow
discrimin
vaccin
anim
infect
anim
diagnost
specif
marker
necessari
meyer
et
al
gener
scfv
ompd
diagnost
purpos
gener
antibodi
suitabl
competit
elisa
use
swine
serum
show
also
difficulti
develop
diagnost
assay
often
hamper
complex
serum
sampl
overview
recombin
antibodi
gener
phage
display
bacteri
pathogen
given
tabl
larg
panel
antibodi
variou
virus
gener
either
immun
librari
use
phage
display
technolog
pan
peptid
recombin
viral
protein
complet
viru
particl
led
identif
antibodi
direct
human
pathogen
virus
sin
nombr
viru
dengu
viru
influenza
viru
veev
noroviru
sar
coronaviru
hepat
c
antibodi
gene
librari
antibodi
select
immun
antibodi
gene
librari
target
eg
western
equin
enceph
viru
weev
hiv
sar
yellow
fever
viru
influenza
viru
semisynthet
librari
also
use
gener
antibodi
specif
influenza
viru
besid
human
anim
virus
antibodi
also
gener
plant
virus
librari
origin
differ
speci
success
employ
isol
virusspecif
antibodi
past
macaqu
mous
chimpanze
llama
chicken
human
origin
virusspecif
antibodi
isol
librari
scfv
format
although
fab
vhh
librari
also
success
use
interest
approach
use
xiao
et
al
use
antibodi
domain
scaffold
gener
binder
hiv
differ
antibodi
characterist
influenc
viru
bind
neutral
neutral
antibodi
prevent
cell
bind
viru
antibodi
higher
neutralizaton
rate
scfv
fab
compar
igg
show
epitop
less
access
igg
format
anoth
interest
exampl
vhh
tryptophan
relev
epitop
bind
essenti
viru
neutral
follow
paragraph
give
detail
exampl
antibodi
gener
use
phage
display
antibodi
engin
differ
viru
group
vaccinia
viru
prototyp
viru
genu
orthopoxviru
rel
larg
dna
viru
genom
kbp
genu
orthopoxviru
includ
variou
speci
monkeypox
viru
cowpox
viru
especi
variola
viru
caus
agent
smallpox
human
natur
occur
smallpox
erad
massiv
vaccin
program
began
howev
vaccin
civilian
popul
conduct
nowaday
potenti
threat
intent
releas
renew
search
safe
effect
smallpox
vaccin
case
fatal
rate
among
unvaccin
subject
report
orthopoxvirus
highli
relat
assum
immun
one
poxviru
goe
along
immun
member
entir
viru
famili
use
immun
scfv
phage
display
librari
construct
vaccinia
viru
immun
patient
panel
human
vacciniaspecif
antibodi
select
plaquereduct
neutral
test
reveal
seven
antibodi
neutral
vaccinia
well
cowpox
viru
vitro
five
antibodi
addit
neutral
monkeypox
viru
antibodi
gener
fab
immun
librari
deriv
vaccinia
viru
immun
chimpanze
convert
chimer
chimpanzeehuman
igg
format
two
antibodi
display
high
affin
vaccinia
protein
k
nm
antibodi
neutral
vitro
vaccinia
smallpox
viru
proof
protect
mice
challeng
vaccinia
viru
even
administ
day
challeng
model
prove
provid
significantli
greater
protect
previous
isol
rat
antibodi
vaccinia
use
model
final
confirm
protect
smallpox
possibl
ebola
viru
marburg
viru
two
filovirus
caus
sever
hemorrhag
fever
possess
high
mortal
human
addit
public
health
concern
associ
natur
outbreak
ebola
viru
might
potenti
agent
biolog
warfar
bioterror
human
antibodi
direct
ebola
viru
select
librari
origin
patient
recov
infect
ebola
viru
outbreak
kikwit
democrat
republ
congo
sever
antibodi
variou
viral
protein
nucleoprotein
envelop
glycoprotein
secret
envelop
glycoprotein
isol
studi
one
antibodi
specif
envelop
glycoprotein
abl
neutral
vitro
fab
neutral
gml
full
igg
neutral
gml
followup
studi
show
effect
protect
vivo
guinea
pig
ebola
challeng
model
antibodi
administ
one
hour
postvir
challeng
interestingli
protect
macaqu
challeng
ebola
even
antibodi
given
twodos
treatment
first
dose
one
day
prior
viral
challeng
second
dose
day
postchalleng
murin
scfv
two
shark
ignar
v
immun
librari
gener
inactiv
zair
ebola
viru
yield
variou
antibodi
specif
viral
matrix
protein
viral
nucleoprotein
interestingli
work
repres
first
exampl
success
target
ignar
v
isol
shark
immun
respons
librari
dengu
viru
denv
member
flavivirida
famili
respons
least
million
symptomat
infect
year
becam
major
health
econom
burden
countri
worldwid
posit
strand
rna
viru
kb
genom
compromis
singl
open
read
frame
four
circul
serotyp
dengu
viru
show
approxim
sequenc
homolog
fab
monoclon
antibodi
dengu
type
viru
isol
chimpanze
immun
librari
two
fab
name
neutral
effici
titer
gml
plagu
reduct
neutral
test
anoth
studi
select
human
scfv
antibodi
specif
dengu
viru
envelop
protein
pan
recombin
fulllength
envelop
protein
domain
iii
denv
envelop
protein
essenti
molecul
virion
assembl
viru
entri
scfv
select
studi
shown
exhibit
inhibitori
effect
denv
infect
vitro
dengu
nonstructur
protein
essenti
viral
replic
host
immun
respons
modul
make
excel
target
dengueinhibit
antibodi
human
fabphag
librari
screen
antibodi
fragment
use
variou
variant
dengu
viru
serotyp
antigen
pan
character
use
altern
dengu
serotyp
round
pan
strategi
result
identif
two
clone
crossreact
four
dengu
serotyp
anoth
studi
select
antibodi
use
phage
display
pan
dengu
viru
particl
directli
captur
supernat
infect
vero
cell
highli
serotypespecif
antibodi
gener
total
nine
antibodi
seven
shown
specif
one
serotyp
one
select
clone
crossreact
dengu
wherea
anoth
clone
show
crossreact
serotyp
despit
select
sole
dengu
particl
interestingli
obtain
antibodi
recogn
sever
strain
distinct
genotyp
within
correspond
serotyp
pan
dengu
envelop
protein
result
identif
antibodi
mousehuman
chimer
fab
librari
crossreact
neutral
cellbas
assay
convers
fulllength
igg
besid
scfv
fab
variabl
domain
heavychain
antibodi
vhh
antibodi
also
select
use
phage
display
technolog
four
round
pan
recombin
denv
protein
posit
clone
select
affin
measur
reveal
k
valu
best
vhh
antibodi
venezuelan
equin
enceph
viru
veev
alphaviru
togovirida
famili
caus
equin
epidem
also
caus
enceph
human
viru
classifi
categori
b
agent
center
diseas
control
prevent
cdc
much
research
done
gener
neutral
antibodi
antibodi
gener
immun
librari
human
donor
target
veev
envelop
glycoprotein
isol
fab
neutral
vitro
time
effect
subsequ
convert
full
igg
format
employ
gener
neutralizationescap
variant
veev
epitop
map
within
anoth
studi
immun
macaqu
librari
use
gener
humanlik
antibodi
one
antibodi
scfvfc
protect
mice
administ
h
postvir
challeng
veev
trinidiad
strain
show
surviv
challeng
ld
howev
scfvfc
abl
neutral
trinidad
strain
vitro
veev
strain
instead
show
neutral
mandatori
vivo
protect
antibodi
anoth
studi
describ
select
antibodi
human
scfv
gene
librari
use
complet
activ
veev
particl
antigen
case
specif
detect
veev
strain
select
antibodi
proven
remark
none
select
scfv
phage
clone
show
crossreact
alphaviru
speci
eastern
equin
enceph
viru
weev
antigen
complex
chikungunya
viru
make
ideal
tool
immunolog
detect
diagnost
alphaviru
speci
two
differ
scfv
antibodi
librari
construct
weev
immun
macaqu
subclon
scfvfc
three
antibodi
librari
specif
bound
weev
elisa
littl
crossreact
alphavirus
found
neutral
vitro
studi
first
antibodi
weev
shown
neutral
vitro
develop
ngml
best
antibodi
neutral
weev
flu
diseas
caus
influenza
virus
last
year
bird
flu
pandem
swine
flu
variant
move
research
focu
due
mani
genet
event
antigen
drift
shift
new
influenza
variant
occur
futur
challeng
vaccin
diagnost
develop
differ
group
develop
antibodi
phage
display
influenza
virus
sui
et
al
select
antibodi
nonimmun
scfv
librari
hemagglutinin
ectodomain
hemagglutinin
trimer
extracelluar
part
consist
stalk
domain
globular
head
domain
identifi
ten
antibodi
bind
trimer
monomer
interestingli
nine
antibodi
share
germlin
framework
antibodi
convert
protect
mice
mgkg
prophylact
therapeut
challeng
model
respect
remark
antibodi
crossneutr
influenza
strain
phage
display
deriv
antibodi
candid
broadspectrum
influenza
immunotherapi
rabi
caus
rabi
viru
infect
central
nervou
system
loui
pasteur
develop
rabi
vaccin
diseas
alway
fatal
current
postexposur
therapi
base
vaccinationa
perform
pasteur
polyclon
antirabbi
immunoglobulin
one
hundr
fortyseven
uniqu
recombin
antibodi
rabi
glycoprotein
select
two
immun
scfv
librari
neutral
street
rabi
virus
test
vitro
best
neutral
antibodi
test
vivo
hamster
rabi
infect
model
antibodi
show
postexposur
protect
iukg
antibodi
analyz
combin
human
antibodi
deriv
somat
cell
hybrid
techniqu
vitro
vivo
model
safeti
mab
cocktail
name
test
clinic
phase
studi
subsequ
phase
studi
antibodi
name
foravirumab
rafivirumab
overview
recombin
antibodi
gener
phage
display
virus
given
tabl
use
phage
display
technolog
larg
panel
antibodi
broad
rang
eukaryot
pathogen
gener
antibodi
direct
pathogen
anim
eg
taenia
solium
protozoa
eg
cryptosporidium
parvum
plasmodium
falciparum
toxoplasma
gondii
fungi
aspergillu
fumigatu
human
pathogen
focu
antibodi
gener
also
veterinari
pathogen
like
myxobolu
rotundu
fish
pathogen
babesia
gibsoni
dog
pathogen
plant
pathogen
like
aspergillu
niger
fusarium
verticilloid
sclerotinia
sclerotiorum
antibodi
gener
studi
deriv
human
antibodi
gene
librari
librari
mous
chicken
camel
macaqu
origin
also
success
appli
phage
display
gener
monoclon
antibodi
eukaryot
pathogen
follow
paragraph
detail
exampl
use
phage
display
gener
antibodi
differ
eukaryot
pathogen
given
aspergillu
fumig
caus
pathogen
allerg
bronchopulmonari
aspergillosi
chronic
necrot
aspergillosi
saprophyt
aspergilloma
highli
lethal
invas
aspergillosi
import
aspergillusrel
diseas
invas
aspergillosi
occur
immunocompromis
individu
exampl
hematopoiet
stem
cell
transplant
solid
organ
transplant
due
sever
earli
diagnosi
crucial
success
treatment
et
al
report
gener
sever
antibodi
bind
specif
fumig
antigen
glycosyl
hydrolas
famili
locat
cell
wall
grow
hypha
antibodi
could
serv
tool
new
diagnost
assay
serum
elisa
histopatholog
immunofluoresc
microscopi
antibodi
describ
studi
isol
two
differ
phagedisplay
scfv
librari
one
macaqu
immun
librari
theoret
divers
independ
clone
human
antibodi
librari
librari
use
two
differ
pan
strategi
first
perform
recombin
antigen
immobil
immunostrip
second
carri
solut
biotinyl
antigen
final
individu
scfv
clone
select
six
clone
deriv
librari
ten
immun
librari
interestingli
antibodi
gener
immobil
antigen
bind
linear
epitop
wherea
antibodi
gener
pan
solut
bind
conform
epitop
seven
antibodi
bound
nativ
antigen
grow
hypha
aspergillu
fumigatu
show
crossreact
aspergillu
speci
candida
albican
malaria
lifethreaten
protozo
infect
red
blood
cell
one
common
mosquitoborn
diseas
current
estim
billion
peopl
tropic
subtrop
countri
live
risk
malaria
human
malaria
elicit
least
five
differ
speci
plasmodium
p
falciparum
p
vivax
p
oval
p
malaria
p
knowlesi
p
falciparum
respons
malariarel
death
global
p
vivax
widespread
parasit
three
differ
approach
gener
antibodi
p
falciparum
use
phage
display
describ
studi
variou
structur
differ
development
stage
parasit
serv
antigen
first
studi
roeffen
et
al
use
two
scfv
immun
librari
construct
blymphocyt
p
falciparum
patient
transmissionblock
immun
gener
antibodi
surfac
protein
p
falciparum
express
zygoteand
macrogamet
stage
potenti
vaccin
candid
sinc
target
transmissionblock
antibodi
taken
mosquito
togeth
blood
meal
block
within
mosquito
intestin
tract
oocyt
develop
pan
perform
extract
gametocyt
immobil
immunotub
elut
perform
competit
mixtur
four
rat
monoclon
mab
recogn
distinct
epitop
epitop
iib
iii
v
interestingli
select
antibodi
clone
bound
epitop
iii
sowa
et
al
report
isol
human
monoclon
antibodi
block
region
plasmodium
falciparum
merozoit
surfac
phage
display
malaria
patient
deriv
scfv
librari
lundquist
et
al
gener
fabimmun
librari
leukocyt
adult
acquir
immun
malaria
three
individu
fab
design
isol
immun
librari
pan
recombin
fragment
merozit
surfac
protein
involv
heme
bind
antibodi
protein
promot
erad
parasit
monocyt
synthet
peptid
ntermin
fragment
even
use
human
clinic
trial
vaccin
antibodi
subclon
format
analysi
bind
antibodi
nativ
parasit
protein
demonstr
three
antibodi
immuno
blot
immunofluoresc
microscopi
also
bound
antigen
fix
permeabil
cell
flow
cytometri
format
show
function
assay
antibodydepend
cellular
inhibit
assay
acdi
inhibit
rate
compar
affinitypurifi
polyclon
antibodi
deriv
immun
donor
format
also
show
inhibit
acdi
lower
compar
overview
recombin
antibodi
gener
phage
display
eukaryot
pathogen
given
tabl
sever
toxin
classifi
cdc
categori
b
agent
definit
see
wwwniaidnihgovtop
biodefenserelatedbiodefensepagescataaspx
relev
diagnost
therapeut
easili
dissemin
result
high
moder
mortal
rate
context
antibodi
phage
display
offer
power
tool
antibodi
select
allow
isol
neutral
antibodi
complet
activ
toxin
special
domain
use
differ
human
antibodi
librari
high
divers
toxin
aim
find
antibodi
bind
cell
bind
domain
toxin
neutral
interact
domain
correspond
cellular
target
mainli
cell
surfac
protein
also
antibodi
direct
transloc
domain
enzymat
domain
neutral
toxicitiy
isol
highaffin
antibodi
specif
target
anim
often
immun
toxoid
nontox
subunit
select
toxin
domain
well
suit
macaqu
construct
immun
librari
macaqu
vgene
similar
human
counterpart
follow
paragraph
give
detail
exampl
antibodi
gener
use
phage
display
antibodi
engin
differ
toxin
far
antibodi
phage
display
success
use
antibodi
select
panel
toxin
classifi
categori
agent
clostridium
botulinum
botul
bacillu
anthraci
anthrax
also
differ
categori
b
agent
staphylococc
enterotoxin
b
ricin
toxin
ricinu
communi
exampl
highrisk
microorgan
especi
serotyp
recogn
toxic
substanc
known
show
ld
ngkg
intraven
rout
ngkg
pulmonari
rout
gkg
oral
rout
bont
compos
disulfid
bondlink
kda
light
chain
kda
heavi
chain
heavi
chain
contain
two
function
domain
hc
hn
respons
toxin
uptak
nerv
cell
receptormedi
endocytosi
transloc
light
chain
across
membran
neuron
cytosol
wherea
catalyt
domain
light
chain
respons
bont
toxic
current
approach
treatment
botul
includ
applic
human
antibotul
immunoglobulin
babybig
equin
antitoxin
serum
human
serum
stock
babybig
limit
equin
antitoxin
may
caus
hypersensit
serum
sick
situat
antibodi
phage
display
provid
technolog
gener
toxinneutr
antibodi
serotyp
instanc
macaqu
immun
librari
use
isol
neutral
scfv
nm
affin
light
chain
bonta
also
antibodi
heavi
chain
relev
serotyp
bont
therapeut
interest
phage
display
technolog
also
use
isol
singl
domain
antibodi
vhh
immun
llama
cocktail
bont
toxoid
af
anoth
approach
gener
human
antibodi
gene
librari
induc
bontaspecif
immun
respons
vitro
immun
furthermor
antibodi
phage
display
use
gener
antibodi
clostridi
toxin
clostridium
tetani
clostridium
difficil
anthrax
anoth
seriou
infecti
diseas
caus
bacillu
anthraci
aerob
gramposit
sporeform
bacterium
found
soil
around
world
bacillu
anthraci
secret
two
toxin
lethal
toxin
lt
edema
toxin
et
compos
two
subunit
lt
consist
lethal
factor
lf
protect
antigen
pa
et
form
edema
factor
pa
demonstr
lt
essenti
role
pathogenesi
anthrax
subunit
pa
basi
current
vaccin
induc
gener
neutral
antibodi
combin
antibiot
commerci
monoclon
antibodi
pa
raxibacumab
commonli
use
treatment
fda
approv
raxibacumab
treat
inhal
anthrax
due
secur
issu
use
antipa
antibodi
alon
question
sinc
pa
could
modifi
lose
recogn
epitop
retain
biolog
activ
altern
antipa
antibodi
antibodi
target
lf
isol
immun
librari
via
antibodi
phage
display
technolog
combin
antipa
antibodi
antilf
antibodi
could
lead
synergist
effect
improv
efficaci
therapi
exampl
bacteri
toxin
classifi
categori
b
agent
staphylococc
enterotoxin
b
seb
staphylococcu
aureu
bacterium
potenti
caus
agent
foodborn
ill
produc
twentyon
type
staphylococc
enterotoxin
caus
symptom
food
poison
abdomin
cramp
vomit
diarrhea
seb
singl
polypeptid
kda
potent
toxin
secret
aureu
superantigen
stimul
cell
lead
overproduct
cytokin
caus
clinic
symptom
fever
hypertens
case
death
phage
display
use
gener
recombin
antibodi
murin
immun
librari
identifi
epitop
sebspecif
monoclon
antibodi
use
peptid
phage
librari
furthermor
human
monoclon
antibodi
seb
isol
synthet
human
antibodi
gene
librari
inhibit
seb
bind
mhcii
phage
display
technolog
also
use
isol
antibodi
ricin
also
classifi
categori
b
agent
cdc
ricin
glycoprotein
castor
bean
plant
ricinu
communi
consist
two
distinct
subunit
rta
rtb
rtb
galactoseand
nacetylgalactosaminespecif
lectin
bind
specif
sugar
residu
cell
surfac
allow
intern
toxic
rta
endocytosi
rta
rna
nglycosidas
irrevers
inactiv
eukaryot
ribosom
lead
inhibit
protein
synthesi
humanlik
antibodi
select
phage
display
macaqu
immun
rta
one
antibodi
picomolar
affin
neutral
biolog
activ
ricin
vitro
furthermor
neutral
vhh
high
affin
select
llama
immun
librari
best
antibodi
abl
neutral
ricin
activ
vitro
assay
use
gml
vhh
addit
differ
toxin
classifi
cdc
categori
b
agent
number
toxin
almost
endless
differ
anim
known
produc
high
potenti
toxin
contain
complex
composit
exampl
tityu
serrulatu
known
brazilian
yellow
scorpion
danger
scorpion
brazil
produc
acid
peptid
call
gamma
toxin
major
toxic
compon
venom
regard
toxin
neutral
antibodi
isol
human
librari
via
phage
display
capabl
protect
mice
procedur
use
bothrop
jararacussu
venom
pit
viper
speci
endem
south
america
use
human
antibodi
gene
librari
differ
antibodi
select
inhibit
phospholipas
activ
venom
vitro
reduc
myotox
vivo
marin
organ
also
produc
toxin
eg
tetrodotoxin
ttx
pufferfish
elisa
enzymelink
immunosorb
assay
scfv
select
human
antibodi
gene
librari
neutral
ttx
activ
vitro
overview
recombin
antibodi
gener
phage
display
toxin
given
tabl
antibodi
phage
display
allow
gener
recombin
antibodi
differ
speci
includ
human
llama
camel
macaqu
shark
mice
antibodi
mainli
deriv
two
type
sourc
immun
librari
immun
librari
prefer
immun
anim
convalesc
patient
avail
offer
chanc
directli
isol
affin
matur
antibodi
immun
possibl
ethic
feasibl
antibodi
gene
librari
altern
approach
antibodi
gener
process
limit
immun
system
use
antibodi
phage
display
varieti
recombin
antibodi
gener
diagnost
therapi
bacteri
viral
pathogen
eukaryot
pathogen
well
toxin
